Therapy of inflammatory bowel disease: what to expect in the next decade

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Current Opinion in Gastroenterology

• Publication date

  2014-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MOG.0000000000000077PMID 24902037
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases.

  2014cited by this paper
• Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

  2014cited by this paper
• A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy.

  2014cited by this paper
• New therapeutic avenues in ulcerative colitis: thinking out of the box

  2013cited by this paper
• Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study

  2013cited by this paper
• 90 Safety and Efficacy of Laquinimod in Inducing Clinical and Biochemical Improvement in Active Crohn's Disease: Results of an Exploratory Trial

  2013cited by this paper
• OC-014 Clinical and Endoscopic Improvement following Hemopoietic Stem Cell Transplantation vs Mobilisatiion alone in Crohn’S Disease

  2013cited by this paper
• 159 Differentiation Between Etrolizumab (Rhumab Beta7) and Placebo in the Eucalyptus Phase II Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate Efficacy and Safety in Patients With Refractory Moderate-to-Severely Active Ulcerative Colitis

  2013cited by this paper
• Vedolizumab as induction and maintenance therapy for ulcerative colitis.

  2013cited by this paper
• Vedolizumab as induction and maintenance therapy for Crohn's disease.

  2013cited by this paper
• Stem cell therapy in inflammatory bowel disease: which, when and how?

  2013cited by this paper
• A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease

  2013cited by this paper
• HMPL-004 (Andrographis paniculata extract) Prevents Development of Murine Colitis by Inhibiting T-cell Proliferation and TH1/TH17 Responses

  2012cited by this paper
• Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

  2012cited by this paper
• Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

  2012cited by this paper
• Drug delivery trends in clinical trials and translational medicine: growth in biologic molecule development and impact on rheumatoid arthritis, Crohn's disease, and colitis.

  2012cited by this paper
• Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis

  2012cited by this paper
• Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

  2012cited by this paper
• A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate

  2012cited by this paper
• P362 Autologous haematopoietic stem cell transplantation without CD34+; cell selection for refractory Crohn's disease: The Milan experience after 5 years

  2012cited by this paper
• Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

  2012cited by this paper
• Certolizumab pegol for the treatment of Crohn’s disease

  2011cited by this paper
• Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

  2011cited by this paper
• Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease

  2011cited by this paper
• The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study

  2011cited by this paper
• Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up.

  2010cited by this paper
• Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease

  2010cited by this paper
• Biological therapies for inflammatory bowel diseases.

  2009cited by this paper
• Expanded Adipose-Derived Stem Cells for the Treatment of Complex Perianal Fistula: a Phase II Clinical Trial

  2009cited by this paper
• S1066 Oral Alpha-4 Integrin Inhibitor (AJM300) in Patients with Active Crohn's Disease — A Randomized, Double-Blind, Placebo-Controlled Trial

  2009cited by this paper
• Oral laquinimod therapy in relapsing multiple sclerosis

  2009cited by this paper
• A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.

  2008cited by this paper
• Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial

  2007cited by this paper
• Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

  2007cited by this paper
• Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

  2007cited by this paper
• Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

  2006cited by this paper
• Infliximab for induction and maintenance therapy for ulcerative colitis.

  2005cited by this paper
• Natalizumab induction and maintenance therapy for Crohn's disease.

  2005cited by this paper
• A Phase I Clinical Trial of the Treatment of Crohn’s Fistula by Adipose Mesenchymal Stem Cell Transplantation

  2005cited by this paper
• A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.

  2004cited by this paper
• Infliximab maintenance therapy for fistulizing Crohn's disease.

  2004cited by this paper
• A controlled trial of natalizumab for relapsing multiple sclerosis.

  2003cited by this paper
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

  2002cited by this paper
• CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease.

  2001influential reference
• Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.

  1999cited by this paper
• Infliximab for the treatment of fistulas in patients with Crohn's disease.

  1999cited by this paper
• Course of Crohn's disease after allogeneic marrow transplantation.

  1998cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Systematic literature review on early clinical evidence for immune-resolution therapies and potential benefits to patients and healthcare providers

  2024cites this paper
• Conditioned secretome of adipose-derived stem cells improves dextran sulfate sodium-induced colitis in mice

  2021cites this paper
• Phloretin Ameliorates Acetic Acid induced Colitis through Modulation of Immune and Inflammatory Reactions in Rats.

  2020cites this paper
• Libertellenone M, a diterpene derived from an endophytic fungus Phomopsis sp. S12, protects against DSS-induced colitis via inhibiting both nuclear translocation of NF-κB and NLRP3 inflammasome activation.

  2020cites this paper
• Bowel Disease : Complexity and Variability need integration

  2018cites this paper
• Rectal Insulin Instillation Inhibits Inflammation and Tumor Development in Chemically Induced Colitis

  2018cites this paper
• Genetically engineered two-warhead evasins provide a method to achieve precision targeting of disease-relevant chemokine subsets

  2018cites this paper
• Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics

  2017cites this paper
• Umbilical cord-derived mesenchymal stem cell extracts reduce colitis in mice by re-polarizing intestinal macrophages

  2017cites this paper
• Therapeutic efficacy of carboxyamidotriazole on 2,4,6‐trinitrobenzene sulfonic acid‐induced colitis model is associated with the inhibition of NLRP3 inflammasome and NF‐&kgr;B activation

  2017cites this paper
• Matricellular Protein Periostin Mediates Intestinal Inflammation through the Activation of Nuclear Factor κB Signaling

  2016cites this paper
• Endothelial Cell-Immune Cell Interaction in IBD

  2016cites this paper
• Overview of biological therapy in ulcerative colitis: current and future directions.

  2015cites this paper
• Eosinophils in Gastrointestinal Disorders: Eosinophilic Gastrointestinal Diseases, Celiac Disease, Inflammatory Bowel Diseases, and Parasitic Infections.

  2015cites this paper
• Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease.

  2015cites this paper
• Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives.

  2015cites this paper
• Pharmacologic therapy for inflammatory bowel disease refractory to steroids

  2015cites this paper
• Medical Management of Crohn Disease

  2013cites this paper
• Clinical and Experimental Gastroenterology Dovepress

  year unknowncites this paper